Hold Rating for TScan Therapeutics Amid Promising Data and Awaited Future Developments

Morgan Stanley analyst Maxwell Skor has maintained their neutral stance on TCRX stock, giving a Hold rating on December 7.

Maxwell Skor has given his Hold rating due to a combination of factors surrounding TScan Therapeutics’ recent data and future prospects. The company presented promising results at the ASH 2025 conference, particularly with their TSC-101 treatment showing favorable relapse-free survival and overall survival rates. However, the statistical significance of these results was not strong enough to warrant a more positive rating, as indicated by the p-values.
Despite the encouraging safety profile of TSC-101, with no severe adverse events reported, the company’s future success hinges on upcoming data expected in the first half of 2026. The management’s plan to enroll additional patients and the anticipated initiation of a pivotal trial in the second quarter of 2026 are critical factors. These elements contribute to the Hold rating, as investors are advised to wait for more conclusive evidence before making significant investment decisions.

In another report released on December 7, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.00 price target.